As of November 10, 2026, Exelixis, Inc. is a publicly traded company (Nasdaq: EXEL). The largest holder reporting an active stake on Schedule 13D is Farallon Capital Partners, L.P., at 5.9%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Vanguard (5.09%) (Schedule 13D/A, January 5, 2026).
Is this your company?
About to sign with, pay or invest in Exelixis, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Exelixis, Inc. a real, registered company?
- Exelixis, Inc. files with the SEC under CIK 939767 (its SEC filings).
- Its shares are listed under the ticker EXEL on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Alameda, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under EXELIXIS, INC. in our court records and SEC 8-K records (as of 2026-11-10).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Farallon Capital Management, L.L.C. (filed 2026-11-09).
Who are Exelixis, Inc.'s owners and officers?
Exelixis, Inc.: incorporated in Delaware; business address in Alameda, California; industry Biological Products, (No Diagnostic Substances) (Schedule 13D/A, 2026-11-09).
| Report | Holder | Share |
|---|---|---|
| Schedule 13D/A, 2026-11-09 | Farallon Capital Management, L.L.C. | 4.9% |
| Schedule 13G, 2026-11-09 | Farallon Capital Management, L.L.C. | 6% |
| Schedule 13D/A, 2026-08-14 | Farallon Capital Management, L.L.C. | 5.6% |
| Schedule 13G/A, 2026-08-12 | Aqr Capital Management, LLC | 4.39% |
| Schedule 13G, 2026-04-29 | Vanguard Capital Management | 5.09% |
| Schedule 13G/A, 2026-03-26 | The Vanguard Group | 0% |
| Schedule 13G, 2026-02-13 | Aqr Capital Management, LLC | 5.09% |
| Schedule 13D/A, 2026-01-05 | Farallon Capital Partners, L.P. | 5.9% |
Questions about who owns Exelixis, Inc.
Who owns Exelixis, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Exelixis, Inc.: Farallon Capital Partners, L.P. (5.9%, Schedule 13D/A, filed 2026-01-05) and Vanguard Capital Management (5.09%, Schedule 13G, filed 2026-04-29).
Who are the largest shareholders of Exelixis, Inc.?
By the share each holder's latest filing reports, the largest holders of Exelixis, Inc. on this page are Farallon Capital Partners, L.P. (5.9%) and Vanguard Capital Management (5.09%).
When did Farallon Capital Partners, L.P. buy into Exelixis, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Farallon Capital Partners, L.P. on this page is the Schedule 13D/A, filed 2026-01-05, reporting 5.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 8 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Exelixis, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Exelixis, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Exelixis, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Exelixis, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 4,870,118 shares (2.0% of shares outstanding), 2,848,063 held directly and 2,022,055 indirectly (Form 4, 2026-05-19).
- , a director: 1,571,438 shares (0.64% of shares outstanding), 18,176 held directly and 1,553,262 indirectly, on a joint filing (Form 4, 2025-11-26).
- Caligan Partners LP, a director: 1,571,438 shares (0.64% of shares outstanding), 18,176 held directly and 1,553,262 indirectly, on a joint filing (Form 4, 2025-11-26).
- , a director: 1,197,595 shares (0.49% of shares outstanding) (Form 4, 2026-05-29).
- , the chief financial officer and executive vice president: 955,040 shares (0.39% of shares outstanding), 952,317 held directly and 2,723 indirectly (Form 4, 2026-05-19).
Shares outstanding: 244,010,895 as of 2026-10-19, from the company's latest SEC cover page.
How much has Exelixis, Inc. raised?
No fundraising or offering filing from Exelixis, Inc. is on file with us.
Keep reading
More on Exelixis, Inc. and the records around it.
Exelixis, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
Companies that share a holder
- Farallon Capital Management, L.L.C. also filed stake reports on 18 other companies: ENANTA PHARMACEUTICALS INC (Aug 2026), InflaRx N.V. (Aug 2026), Savara Inc. (Aug 2026)
- Farallon Capital Partners, L.P. also filed stake reports on 19 other companies: BridgeBio Pharma, Inc. (May 2026), InflaRx N.V. (May 2026), Beta Bionics, Inc. (May 2026)
- AQR Capital Management, LLC also filed stake reports on 190 other companies: Bold Eagle Acquisition Corp. (Nov 2026), Centurion Acquisition Corp. (Aug 2026), FG Merger II Corp. n/k/a BOXABL Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/exelixis